Conexeu Sciences Inc. Common Stock(CNXU)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$2.18
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CNXU

11/13/2026: CNXU (1-star) is currently NOT-A-BUY. Pass it for now.

Conexeu Sciences Inc. is a Nasdaq-listed clinical-stage biotechnology company developing proprietary extracellular matrix scaffolds designed to naturally regenerate human tissue. The company's primary strength lies in its versatile CXU biomaterial platform, which targets high-growth opportunities in advanced wound care and medical aesthetics. Its central investment story centers on capturing emerging demand for biological tissue restoration, particularly addressing soft-tissue loss linked to rapid weight-loss trends. However, the company faces execution, funding, and regulatory risks typical of pre-revenue small-cap firms seeking FDA clearances against well-capitalized competitors. Conexeu suits aggressive growth investors willing to tolerate high volatility, with key developments to monitor including upcoming regulatory filings and manufacturing scale-up progress.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company offers exposure to an emerging regenerative medicine platform targeting multi-billion dollar clinical markets.
Momentum investorStrong fit while signal remains positiveSmall-cap biotech status and regulatory catalysts can trigger sharp trading volume spikes when sentiment is favorable.
Value investorWeak fitThe absence of commercial revenues and ongoing operating losses make traditional valuation metrics inapplicable.
Dividend investorWeak fitThe company does not pay dividends and retains all capital to fund clinical and regulatory development.
Low-risk investorWeak fitEarly-stage pre-revenue biotechnology stocks carry high price volatility, execution risk, and regulatory uncertainty.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighSmall-cap equity status and low initial market capitalization expose shares to sharp price fluctuations.
Valuation riskHighValuation relies heavily on future clinical and regulatory success rather than current earnings or revenue.
Competition risk (biomaterial and medical aesthetics competition)Medium / highWell-capitalized medtech competitors hold entrenched market shares in wound care and soft-tissue aesthetics.
Business qualityMediumWhile scientific foundations and peer-reviewed data are promising, commercial viability remains unproven.
Dividend incomeLow / noneThe company is focused entirely on clinical growth and provides no income return to shareholders.
Execution riskHighFuture prospects depend directly on meeting regulatory filing timelines and scaling manufacturing successfully.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 67.21M USD
Price to earnings Ratio -
1Y Target Price 20
Price to earnings Ratio -
1Y Target Price 20
Volume (30-day avg) 338.8K shares
Beta -
52 Weeks Range 1.93 - 18.79
Updated Date 11/15/2026
52 Weeks Range 1.93 - 18.79
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.61

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Insufficient Data
PRICE PATH

Insufficient Data

The stock demonstrates a Insufficient Data price path pattern.

Insufficient Data
PRICE STABILITY

Insufficient Data

The stock price exhibits a Insufficient Data stability pattern.

Analysis of Past Performance

Type Stock
Historic Profit 0%
Avg. Invested days 0
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CNXU receives a 2-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
CNXU has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-731.5%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
CNXU's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
CNXU's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-731.5%, negative) and free-cash-flow growth (-649.0%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 9.1% and approximately 53.4% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 47.77% supports management-shareholder alignment.

Top 5 Institutional Investors

Renaissance Technologies Corp 0.39%
UBS Group AG 0.04%
Morgan Stanley - Brokerage Accounts 0.02%
Citigroup Inc 0.02%
Hollencrest Securities, LLC 0.00%

Unit Economics (Per $1K Revenue)

★★★★★
CNXU generates approximately $0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
CNXU has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Regenerative Wound Care (Pipeline)Investigational extracellular matrix scaffold products targeted for FDA 510(k) clearance to treat acute and chronic wounds.This represents the company's near-term commercial pathway upon securing regulatory approval.
Medical Aesthetics & Soft-Tissue Restoration (Pipeline)Investigational biomaterials designed for facial rejuvenation and larger-volume restoration addressing tissue loss.This serves as a larger secondary growth vector targeting multi-billion-dollar aesthetic markets.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 65.62M
Price to Sales(TTM) -
Enterprise Value 65.62M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 30.83M
Shares Floating 16.47M
Shares Outstanding 30.83M
Shares Floating 16.47M
Percent Insiders 47.77
Percent Institutions 9.11

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.